A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER).

Trial status: Authorised 3. Change From Baseline in eGFR at Week 104 [Time Frame: From Baseline at Week 104]., 4. Time to Kidney Disease Progression Through Week 104 Kidney disease progression defined as greater than or equal to (≥) 30% decline in eGFR, end stage kidney disease, or non-accidental death. [Time Frame: From Baseline Through Week 104]., 1. Change from baseline in serum Gd-IgA1 at Week 36, 2. Proportion of subjects to achieve hematuria resolution at Week 36 (among subjects with hematuria at baseline) 1. Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (uPCR) at Week 36 [Time Frame: From Baseline at Week 36]., 2. Total Estimated Glomerular Filtration Rate (eGFR) Slope Through Week 104 [Time Frame: From Baseline Through Week 104].

3. Change From Baseline in eGFR at Week 104 [Time Frame: From Baseline at Week 104]., 4. Time to Kidney Disease Progression Through Week 104 Kidney disease progression defined as greater than or equal to (≥) 30% decline in eGFR, end stage kidney disease, or non-accidental death. [Time Frame: From Baseline Through Week 104]., 1. Change from baseline in serum Gd-IgA1 at Week 36, 2. Proportion of subjects to achieve hematuria resolution at Week 36 (among subjects with hematuria at baseline)

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 181 participants